FGFR2 and urothelial carcinoma: Amplification of FGFR2 was found in up to 10% of gastric cancers [46,47] and FGFR2 gene fusions in up to 20% of intrahepatic cholangiocarcinomas and up to 6% of urothelial carcinomas [35].